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ABSTRACT
ASSESSMENT OF A MARINE POLYSACCHARIDE FOR USE AS EXCIPIENT
IN PHARMACEUTICAL HOT-MELT EXTRUSION

by
Qing Ye
Pharmaceutical Hot Melt Extrusion (HME) is currently investigated by both industry and
academia as a method for manufacturing solid oral dosages with improved bioavailability
of poorly-water soluble active pharmaceutical ingredients (APIs) and control drug release
of water-soluble APIs. Although HME is traditionally utilizing synthetic polymers to
produce such dosages, biopolymers constantly gain ground by virtue of renewability,
biocompatibility and in some cases biodegradability. In this work, the possibility of using
Keltone, a marine polysaccharide derived from brown seaweed, as a polymeric excipient
for pharmaceutical HME is explored. Keltone is insoluble in acidic pH and soluble in
basic pH, therefore making it suitable for intestinal drug release. The processability of
Keltone

by extrusion using water

Diphenhydramine

Hydrochloride

and

and

Eudragit

Clotrimazoleas

EPO as plasticizers,
as

active

and

pharmaceutical

ingredients is assessed. The amount of residual water in the extrudates is determined by
thermogravimetric analysis. The thermal transitions of the extrudates are determined by
Differential Scanning Calorimetry.
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CHAPTER 1
INTRODUCTION

1.1 Objective
Pharmaceutical Hot-melt Extrusion (HME) is currently pursued by both industry and
academia as a “green”, solvent-less process technology for manufacturing oral dosage
formulations and medical devices in a continuous and controlled fashion (Crowley et al.,
2007). In this work, the possibility of using Keltone, a marine polysaccharide derived from
brown seaweed, as a polymeric excipient for pharmaceutical HME was explored. Keltone is
insoluble in acidic pH and soluble in basic pH, therefore making it suitable for intestinal
drug release. The processability of Keltone by extrusion using water and Eudragit EPO as
plasticizers, Diphenhydramine Hydrochloride and Clotrimazoleas active pharmaceutical
ingredients (APIs) were assessed.

1.2 Background Information
HME is primarily utilized to improve the bioavailability of poorly-water soluble,
crystalline active pharmaceutical ingredients (APIs) by dissolving them into water-soluble
polymer excipients. At the same time, controlled-release oral dosages can be manufactured
by dispersing water-soluble APIs into water-insoluble or swellable dissolution
rate-controlling polymers (Terife et al., 2012). Combinations of the above can also be
realized. Moreover, compared to traditional pharmaceutical processing methods, HME is
appreciably less expensive manufacturing process and has the advantage of shorter and
more efficient times to the final product through reduction of the processing steps involved
(Repka et al., 2007).
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Although HME and other pharmaceutical manufacturing methods utilize
predominantly synthetic polymers as excipients, biopolymers or naturally occurring
polymers constantly gain ground by virtue of renewability, biocompatibility and in some
cases, biodegradability. The quest for a green technologies and the growing public
awareness of climate changes stimulate the surging demand for green and renewable
products with a low carbon foot-print. Moreover, the rapidly growing world population,
aspires to a higher quality of life. Ultimately, this will lead to drastically increased demand
for energy and resources. In this way, biopolymers play a prominent role (Mulhaupt,
2014). They are made from renewable materials, and so do not use up fossil fuel resources
and should result in fewer overall greenhouse gas emissions. And many of them are
naturally biodegradable and so will not litter the environment after use (Evans, 2014).
According to figure published last year by European Bioplastic, global biopolymer
production capacity increased from 250,000 tons in 2009 to almost 1.4 million tons in
2012, and is predicted to rocket to almost 6.2million tons by 2017.
In this work, the possibility of using a sodium alginate, Keltone, as an excipient to
manufacture oral dosage formulations with delayed release properties via HME are being
explored. Sodium alginate is an anionic polysaccharide that is found in the cell walls of
brown algae (Sperger et al., 2011). It is a linear co-polymer with homopolymeric blocks of
(1-4)-linked β-D-mannuronate (M) and α-L-guluronate (G) covalently linked together in
different sequence blocks. The monomers can appear in homopolymeric blocks of
consecutive G-residues, consecutive M-residues or alternating M- and G-residues (Soares
et al., 2004). Alginate is one of the most popular hydrogels and has been successfully
employed for many applications in the human body, including tissue implants. Several
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commercial products containing ultrapure alginate (in accordance with GMP/ISO 9000
guidelines) are extensively used as excipients in the pharmaceutical industry (Dornish et
al., 2001).
Keltone is a pH-depended solubility (insoluble in low pH, soluble in basic pH)
material, which makes it a good candidate for intestinal drug delivery. Besides, Keltone is
of high hydrophilicity biopolymer, which may play an important role in the targeting of
gastrointestinal tissue in the development of orally administered drugs. Epithelial cells in
gastrointestinal tissue are always covered by protective mucus. A feasible approach is to
delay the transit through the gut, increasing the likelihood of contact between the delivery
device and the tissue (Castro et al., 2008). By this way, Keltone can be a potential
candidate of excipient for controlled-release drug.
However, as a biopolymer, Keltone has two major drawbacks: Poor thermal
properties (although crystalline, it has no practical melting point as it thermally degrades
before it melts) and high water content that restrict it to a number of main applications. As
a result, these properties can make it difficult to process the biopolymers into the final
product. In this work, the possibility of using Keltone as an excipient to manufacture oral
dosage formulations via HME was examined, in an effort to investigate the possibility of
expanding its uses in pharmaceutical product applications.
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CHAPTER 2
LITERATURE REVIEW

2.1 Pharmaceutical Hot-melt Extrusion
Hot-melt Extrusion (HME) is an emerging continuous processing technology for the
development of various solid dosage forms and drug delivery systems. In the last few
decades HME has attracted increased attention from both the pharmaceutical industry and
academia. Pharmaceutical Hot-melt Extrusion (HME) is a term that the pharmaceutical
sector adopted to differentiate it from traditional oral dosage producing techniques, such as
direct compression and tableting. HME is primarily utilized to improve the bioavailability
of poorly-water soluble active pharmaceutical ingredients (APIs) by dissolving them into
water-soluble polymers. At the same time, its potential of manufacturing controlled-release
oral dosages by dispersing water-soluble APIs into water-insoluble or rate-controlling
polymers make it a promising technology in pharmaceutical industry.
Due to its versatility in embracing a wide spectrum of applications, HME offers
many advantages over conventional pharmaceutical production. HME is a solvent-free
process, waiving the need for additional production stages (e.g., time-consuming drying
steps), which also makes the process environmentally friendly. There exists a wide range
of dosage forms which can be manufactured via HME (granules, pellets, tablets, ﬁlms,
sheets, rings, etc.), depending on the shape of the die and/or the post-processing technique
(pelletizing, milling, calendering, injection molding, etc.). A uniform dispersion of API in
the molten polymer result from the intense mixing and agitation imposed by the rotating
screw during extrusion. The drug release profile offered by HME products via proper
selection of the polymers used during HME is highly versatile. Solid solutions are an
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efficient approaching the delivery of Biopharmaceutics Classiﬁcation System (BCS) class
II compounds because of the improved absorption and therapeutic efficacy. On the other
hand, HME is also an excellent tool to create sustained-release formulations when, for
example, a hydrophobic polymer is extruded with a highly water-soluble drug. In this case,
API is leached from the matrix much slower than compared to an equivalent compressed
tablet (Gogos et al., 2012).
The main drawback of HME is related to the thermal processing, limiting its
application for thermo labile components. Degradation of the drug (API) and excipients
may occur during HME because of high processing temperatures and heating due to
viscous energy dissipation. However, changes in the conﬁguration of the equipment (screw
conﬁguration, twin-screw extruders) or the addition of plasticizers can reduce process
temperature and residence time to avoid thermal degradation during processing (Gogos et
al., 2012). Additionally, there is a shelf-life stability concern arising from the
thermodynamic tendency of the API to revert to its crystalline form at ambient
temperatures. This will be resisted by the very low mobility of the dissolved API molecules
in the Glassy excipient polymer matrix.
HME involves the use of single or more commonly twin rotor extruders for the
melting of usually water-soluble polymeric excipients, mixing them with APIs and
pumping the homogeneous mixture through a die to form an extrudate. Processes of
pharmaceutical HME can be classified into two categories. Case I, where the processing
temperature is above the melting temperature (semi-crystalline polymer) or the glass
Transition temperature of an amorphous polymer(Tg>50–100◦C) but below the melting
point of a crystalline API. Case II, the processing temperature is above both the melting or
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glass transition temperature of semi-crystalline or amorphous polymers, respectively, and
above the melting point of the API (Gogos et al., 2012).

2.1.1 Elementary Polymer Processing Steps Taking Place in HME
From a polymer processing perspective, HME involves five elementary steps: handling of
particulate solids, melting, pressurization and pumping, mixing, and devolatilization and
stripping (Tadmor and Gogos, 1979). For HME pharmaceutical processing, dissolution of
the API in the molten excipient is an additional and most important elementary step, along
with melting which precedes it and mixing which assists and speeds up dissolution.
As co-rotating twin-screw extruders (co-TSEs) are more commonly used in HME
process development and industrial practice, the following briefly reviewed features of the
elementary steps of HME concern co-TSEs.
2.1.1.1 Particulate Solids Handling (PSH). In co-rotating twin-screw extruders
(co-TSEs), which are commonly used in HME process development, the particulate solid
ingredients are fed gravimetrically or volumetrically controlled at constant rates. These
rates are smaller than those needed to fully fill the parallel channels of the co-TSE,
resulting in ‘starve-fed’ processing. Particulate solids handling in co-TSEs may result in
spatial particle segregation if the relative sizes or shapes of the API and the excipient are
very different, due to different air resistive forces and different particle/wall kinematic
friction coefficients. It is also worth noting that polymer excipients are commonly
hygroscopic, so they may have to be dried prior to dry mixing with the API particulates.
2.1.1.2 Melting. The available melting mechanisms of co-TSEs are conductive melting of
the starve-fed loose particulates by the hot barrel, which is significant for the small
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co-TSEs used in HME development, where the surface-to-volume ratio is large. However,
for larger-diameter co-TSEs, reverse-screw or reverse-kneading elements are used to
create a filled section in which the packed particulates undergo repeated volume-wide
deformations before exiting the fully filled region. During this process, the very powerful
melting mechanism of plastic energy dissipation (PED) is important and possibly
dominant. It is also worth pointing out that the repeated large compressive deformations
taking place in full kneading blocks generate heat by PED, but also induce
particulate-to-particulate frictional heating and localized melting because of frictional
energy dissipation (FED) (Tadmor, 2001) (Gogos, 1998).
2.1.1.3 Devolatilization. Devolatilization refers to the removal of low levels of volatiles of
the order of 1000 ppm, dissolved in the molten matrix. It is carried out in co-TSEs in
partially filled sections isolated from both the upstream and downstream sections by ‘melt
seals’ so that vacuum can be applied. Under vacuum conditions, the dissolved molecules
cause bubbles to be formed in the flowing melt stream (much like the bubbles formed by
opening a carbonated refreshment container) which, when they reach the melt–vacuum
interface, burst and are removed (Tadmor and Gogos, 2006).
2.1.1.4 Pumping and Pressurization. After the accomplishment of all the other
elementary steps, the molten charge need to be pumped through a die which shapes the
exiting streaming operations such as pelletization and sheet, ﬁlm, tube or proﬁled
cross-sectioned products. Drag-induced pumping and pressurization is the flow
mechanism enabling both co-TSEs and SSEs to be the pumps of choice for viscous ﬂuids.
As co-TSEs are fully intermeshing (and self-wiping, which is an advantage for HME
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operations), they are ‘locked in’ with wide channels which are incapable of generating as
high pumping pressures as single screw extruders, which can have shallow channels.
2.1.1.5 Dispersive and Distributive Mixing. The mixing process in single- and
twin-screw extruders, which is the most important elementary steps in the processes of
HME, is generally categorized into two types: (a) dispersive mixing and (b) distributive
mixing.
Dispersive mixing refers to the process involving the particle size reduction of
cohesive components such as solid ﬁllers (by de-agglomeration) or liquid droplets (by
droplet deformation and break-up). Distributive mixing refers to distributing
de-agglomerated particulates uniformly throughout space, or stretching the interfacial area
between the components lacking a cohesive resistance and distributing them uniformly
throughout the product volume. Dispersive mixing is dictated by the magnitude of the
laminar shear and extensional stresses and the type of flow generated by the processing
equipment, whereas distributive mixing is dictated only by the flow-generated strains.
According to these definitions, the mixing of miscible liquids is regarded as distributive
mixing, whereas mixing of hard solid agglomerates, immiscible liquids, and soft
agglomerates is regarded as dispersive mixing (Tadmor and Gogos, 2006).The dispersive
and distributive mixing of solid agglomerates is schematically shown in Figure 2.1.
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Dispersive
Mixing

Not Mixed

Well-Mixed
Dispersively and
Distributively
Distributive
Mixing

Figure 2.1 Dispersive mixing and distributive mixing of solid agglomerates and
immiscible liquid droplets (Tadmor and Gogos, 2006).
Source: Tadmor Z., Gogos C.G., 2006.Principles of Polymer Processing.2nd edition. Wiley-Interscience,
New Jersey.

2.1.2 Melting and Dissolution in Extrusion.
In the process for pharmaceutical HME, dissolution of the API in the molten excipient is an
additional and most important elementary step, along with melting and mixing.
The physical mechanisms that can bring about melting or heating of any substance
are included in the terms of the thermal energy balance (Tadmor and Gogos 2006).

(

)

(

)

(2.1)

The internal energy of a material can be raised by four sources as indicated in
Equation 2.1, where is the density,

is the internal energy and t is the time. (
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)presents the net rate of internal energy increase per unit volume from an outside source
by heat conduction; (

)presents the (reversible) rate of internal energy increase per

unit volume by compression; [ (

)]presents the (irreversible) rate of internal energy

increase by flow and deformation; and Ṡ presents an additional possible homogeneous
energy source.
Melting of polymers is generally classified into conduction melting, compressive
melting, deformation melting and homogeneous internal melting. Conduction melting is
the most common mode, which raises the temperature of a solid and melts it. As the surface
temperature of the solid is raised, a molten layer is formed and it grows with time. Thermal
conductivity, attainable temperature gradients, and available contact area between the
heating source and the melting solid are the rate-controlling factors of conduction melting.
For polymers which have with low thermal conductivity and temperature
sensitivity, the conduction melting is inefficient. However, in flood-fed single screw
extruders, drag-induced melt removal takes place. The SSE quickly removes the freshly
molten material from the vicinity of the high temperature zone, which reduces the risk of
degradations. Also, it generates heat via viscous energy dissipation, which increases the
efficiency of melting.
Deformation melting involves irreversible conversion of mechanical energy to
heat. It is significant, in viscous liquid, especially when the shear rates under processing
condition are high. In the melting step of polymer processing, repeated deformation is
imposed on a compacted bed of particulate solids, which generates significant, but
non-homogeneous heat energy, called plastic energy dissipation (PED) and frictional
energy dissipation (FED) for individual polymeric particles undergoing repeated
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deformations and generating heat within the particle and the mechanical energy dissipated
into heat via inter-particle friction, separately. PED and FED play predominant role in
processing equipment, in particular in co-rotating twin screw extruders (Co-TSEs). In this
case, the thermal energy equation can be written as (Tadmor and Gogos, 2006):

(2.2)

where

is the density of solid,

temperature. (

is specific heat of solid.

presents change of

) is rate of internal energy addition by conduction per unit volume.

Since the fact that polymer solids and melts are virtually incompressible and other
homogeneous internal melting, like dielectric heating, are limited in polymer processing
practice, according to criteria of avoiding thermal degradation and achieving high
processing rates, the melting mechanisms for polymers are summarized as: conduction
melting with forced melt removal (by SSE), plastic energy dissipation (PED) and frictional
energy dissipation (FED) (by twin rotor devices), and dissipative mix-melting (DMM) (by
twin rotor co- and counter- rotating devices) (Tadmor and Gogos, 2006).
Co-rotating twin screws with only conveying elements act similarly to single
screw, which convey and compress the PM by a drag-induced mechanism, then melt by a
drag-induced melt removal mechanism. However, because of their unique time-varying
screw-to-screw interactions taking place, additional physical mechanisms emerge, which
may primarily affect the elementary step of melting and mixing. In other configurations of
TSEs, due to the addition mechanisms, melting and mixing steps are carried out more
efficiently and uniformly, thus narrowing the residence time distribution (RTD) in the
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molten state. In SSEs, on the other hand, some of the polymer melts early in the extruder
and some at the very end, and hence, the RTD in the molten state is rather broad.
Melting in Co-TSEs with intense kneading blocks takes place primarily and most
commonly in the kneading elements where particulates are fully compacted because of a
flow restriction. The evolution of melting in such filled kneading-elementary channels was
studied experimentally by Kim and Gogoset.al (Gogos et al., 1998). They found that
inter-particles FED takes place early and does not require full compaction. At full
compaction, PED becomes dominant melting mechanism.
HME processes can be generally classiﬁed into two categories(Gogos et al.,
2012):Case I: in which the processing temperature is above the melting temperature
(semi-crystalline polymer) or the softening temperature of an amorphous polymer
(Tg>50–100◦C) but below the melting point of a crystalline API. Case II: in which the
processing temperature is above both the melting or softening temperature of
semi-crystalline or amorphous polymers, respectively, and above the melting point of the
API.
Case I provides a viable dissolution path which minimizes or circumvents the
thermal degradation issue of drugs resulting in a desirable polymer-drug solid dispersion or
solid solution, in which the solid API acts as a solute dispersion and the polymer excipient
melt acts as a highly viscous solvent. On the other hand, it is expected that the dissolution
rates and the solubility are larger in the case that the processing temperature is higher.
Figure 2.2 shows its physical model schematically.
The premixed drug (black) and polymer particles (white) are fed into the batch
mixer or an extruder. The polymer particles start melting due to the conductive heat from
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the mixer or extruder barrel and frictional and plastic energy dissipation for co-TSEs,
leading to the solid drug particles being suspended in a continuous polymer melt matrices.
While suspended at the processing temperature, which favors dissolution assuming
intermolecular forces compatibility between the API and the excipient, the drug molecules
start dissolving and create a mass-transfer boundary layer around each drug particles. This
layer is continuously wiped away and replaced by fresh polymer melt around each API
particulate by the laminar distributive flow of the mixer. The same laminar mixing flow
helps the drug molecules to diffuse and mix distributively into the molten excipient. The
size of suspended drug particles diminishes as the diffusion continues until the particles
disappear and a homogeneous solution formed or until the limit of API solubility at the
processing temperature is reached. In the latter case, they reach a minimum average size
and remain suspended. The dissolution of the drug in the polymer melt in an extruder is
achieved by laminar forced convective mass transfer involving the dissolving and
dissolved API molecules.
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Figure2.2 Schematic representation of the morphological changes of the drug and
polymer system in the solution formation process (Case I).
Source: C. G. Gogos, H. Liu and P. Wang, “Laminar Dispersive and Distributive Mixing with Dissolution
and Applications to Hot Melt Extrusion”, Chapter 12 in Hot Melt Extrusion: Pharmaceutical Applications,D.
Douroumis Ed., John Wiley and Sons Ltd, 2012

The main task of Case I is to completely dissolve drugs in polymeric melt within
the shortest possible residence time without raising the processed stream melt temperature.
Case II involves liquid – liquid mixing between miscible or partially miscible
components. The morphology changes are shown in Figure 2.3.
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Figure 2.3 Schematic representation of the morphological changes of the drug and
polymer system in the solution formation process (Case II).
Source: C. G. Gogos, H. Liu and P. Wang, “Laminar Dispersive and Distributive Mixing with Dissolution
and Applications to Hot Melt Extrusion”, Chapter 12 in Hot Melt Extrusion: Pharmaceutical Applications, D.
Douroumis Ed., John Wiley and Sons Ltd, 2012

The premixed drug (black) and polymer (white) particles are fed into an extruder
and conveyed by the conveying elements. The polymer particles melt first due to the
energy input from the barrel and frictional and plastic dissipation. After the polymer
particles totally or partially melt, the drug particles suspended in the molten polymer melt
rapidly, and the drug droplets begin to be deformed by the mixing laminar flows of the
polymer melt rapidly, and the drug droplets begin to be deformed by the mixing laminar
flows of the polymer melt. After that, the drug liquid phase breaks up into much smaller
droplets due to the competition of surface tension and flow stress. The small droplets are
deformed along the shear direction. With numerous very small droplets, which have an
enormous surface, diffusion between the droplets and the polymer predominates causing
the droplets to disappear, creating drug – polymer solution.
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Similarly to the dissolution of drugs in an aqueous medium, the dissolution of drug
particulates in molten polymeric excipients during HME can also be described by the
Noyes–Whitney equation

(

)
(2.3)

where D is the diffusion coefficient; A is the total surface area of the drug exposed to the
dissolution media; Cs is the saturation solubility of the drug in the liquid which (for
HME)is the excipient melt; C describes the concentration of the dissolved solid phase in
the bulk at time t; h represents the diffusion boundary layer at the solid-liquid interface; and
V is the volume of the dissolution medium. The variables influencing the dissolution rate of
drug particulates in the excipient melt can be grouped into three categories: process,
equipment, and material.
In both the diffusion and dissolution cases, the particle sizes of API in the molten
excipient – API system play a significant role. The diffusion rate as well as the dissolution
rate of drug particulates in polymer melt will increase if the total surface area of the drug
particulates exposed to the dissolution media increase. Furthermore, the narrower the drug
particle size distribution, the more uniform the total dissolution time distribution needed
for complete dissolution of drugs in polymer melt will be (Gogos et al.,2012).

2.2 Characterization Methods
The objective of processing a formulation via HME is to transform thermoplastic materials
into homogeneous extrudates with a speciﬁc shape. As for a processing of pharmaceutical
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formulation, the objective is to dissolve all or partial of the APIs into the polymeric
excipient matrixes and fix the mas the amorphous form, then pump them through the die. In
order to achieve these objectives, the materials require a substantial energy uptake which is
provided by elevated temperatures, high shear forces and pressure to enable the intense
mixing of drug and excipient during processing. To characterize the physical nature of
extrudates at molecular or microscopic level, several methods can be used. An overview of
the most common techniques for physicochemical characterization of HME-processed
formulations is provided in the following sections.

2.2.1 Thermo-analytical Methods
Knowledge of the thermal behavior of the drug and polymers incorporated in the
formulation is an essential aspect of dosage form development for HME, as product
performance in terms of dissolution, bioavailability and stability highly depends on its
thermal properties.
The most common application of differential scanning calorimetry (DSC) for HME
formulations is the assessment of drug crystallinity following HME processing and during
storage, in order to determine its impact on drug release and bioavailability. In DSC tests, it
is generally accepted that the absence of endothermic melting peak of the crystalline drug
indicates that the drug is present in an amorphous rather than crystalline form. The crystal
detection limitation of DSC is about 2% (Leuner, 2000). The DSC device maintains the
same programmed temperature in each well and records the power required to achieve this.
If a transition takes place in the sample, a characteristic excursion in the measured
differential power is observed (Thompson, 1985).
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During development of an HME formulation, thermal analysis is essential to
determinethe process conditions during HME, based on the thermal stability of the
individual components as determined via differential scanning calorimetry (DSC) and/or
thermal gravimetric analysis (TGA) .

2.2.2 Microscopy
Optical can help determine the existence of drug crystal regions and the size as well.
Although the resolution of polarized light microscopy (PLM) is approximately at 1μm, the
birefringence of the crystal drug imparts a sharp and distinct contrast against the
amorphous (dark) excipient. Yoo et al. studied the miscibility/stability for 24 binary solid
dispersion systems and found that the sensitivity to crystal detection was polarized light
microscopy (PLM)> differential scanning calorimetry (DSC)>X- ray Diffraction(XRD)
(Yoo, 2009).
Hot stage microscopy (HSM) can be used to visualize the thermal events of sample
formulations through a microscope during heating and/or cooling steps. Lloyd et al. found
that HSM is far more sensitive to the presence of small quantities of solid drug than DSC
(Lloyd, 1997) when studied the preparation of a solid dispersion of acetaminophen and
polyethylene glycol (PEG) 4000.
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CHAPTER 3
MATERIALS AND METHODS

3.1 Materials
Keltone (LVCR) (FMC Biopolymer), A low viscosity anionic marine polysaccharide was
used as a biopolymeric excipient (Figure3.1a). Diphenhydramine Hydrochloride (DMN)
(BCS I) (Sigma Aldridge) (Figure3.1b) and Clotrimazole (CLO) (BCS II)(Sigma
Aldridge) (Figure3.1c)were used as model APIs, respectively. Distilled water was used as
a fugitive plasticizer for Keltone. In some experiments, Eudragit EPO (Figure3.1d) was
used as a co-polymer/plasticizer for Keltone. The choice of DMN as API and water as
plasticizer was due to earlier solvent casting experiments at Polymer Processing Institute
(PPI) where it was showed that DMN forms solid solutions in Keltone in the presence of
excess water. Further data to support the use of water as a plasticizer was the
incompatibility (recrystallization) of polyethylene oxide (PEO) and the low boiling point
of triethyl acetate (~127°C), both commonly used FDA-approved plasticizers in the
pharmaceutical industry.
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a

b

c
d

Figure 3.1 Molecular structures of (a) Keltone (sodium alginate), (b) Diphenhydramine
Hydrochloride, (c) Clotrimazole, (d) Eudragit EPO.

3.2 Extrusion
Extrusion was carried out in the Leistritz Nano16 Co-TSE (Leistritz). Figure 3.2 shows the
appearance of Nano16 Co-TSE. Thisvery small laboratory extruder has two fully
intermeshing, co-rotating, 16 mm in diameter screws equippped with neutral kneading
blocks, which are shown in Figure 3.3. Nano16 Co-TSE has four heating barrel zones (3
zones + die) while the temperature in the feeding zone can be controlled externally via a
jacket. A 1 mm capillary die was used to extrude all formulations.The physical mixture
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was fed to the extruder using the AccuRate 102M single-screw volumetric feeder (Schunck
Corp).

Figure 3.2 Overview of processing zones of Nano16 Co-TSE.

Figure 3.3 Appearance of the co-rotating screws.
Water was injected at a constant rate via a siringe pump connected to zone I (after
the feeding zone). The total feeding rate (Particulates and water) to the extruder was kept
constant during the processing of all formulations at 2 g min-1.
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Physical mixtures of excipient and API were prepared by tumbler mixing at 50 rpm
for one hour.

3.3 Thermo Gravimetric Analysis (TGA)
The Perkin Elmer Thermogravimetric Analysis 7 was used in this work. The ramp mode
was used to determine the water content of Keltone and residual water content of the
extrudates. The samples were placed in an aluminum pan and heated from 30C to 250C
at a heating rate of 10C/min under air. Preliminary experiments in the TGA under both air
and nitrogen atmospheres, showed that the degradation of Keltone and its physical
mixtures (PMs) is thermal so there was no need for a nitrogen blanket during processing.
Isothermal mode was used to determine the stability of the materials at the processing
temperature. In isothermal heating tests, powders were quickly heated to 150C at a rate of
40C/min and held isothermally for 10 minutes.

3.4 Differential Scanning Calorimetry (DSC)
The thermal transitions of raw materials, PMs and extrudates during heating were
determined using a Metler Toledo Polymer DSC.

3.5 Hot-Stage, Polarized Light Microscopy (PLM)
A hot stage (Mettler FP90) was used in conjunction with a Carl Zeiss microscope
(Thornwood, NY)to observe morphology evolution of extrudate samples under polarized
light. The heating rate was set 20C/min from 30 to 160C. Pictures were taken every
10C.
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CHAPTER 4
RESULTS AND DISCUSSION

4.1 Background
Previous work at PPI had showed that (a) Keltone could not be extruded by itself unless a
plasticizer (PEO in this case) was added. In addition it was found that Indomethacin (IND)
could not be dissolved in Keltone by itself. It may be a result from that both Keltone and
IND are anionic materials. IND was found to dissolve in a formulation with both Keltone
and PEO, however the product was found to be unstable following extrusion (both PEO
and IND recrystallized). To determine if the dissolution ability of Keltone is related to its
charge, we used Diphenhydramine Hydrochloride (DMN), which is a cationic drug. Based
on literature(M. Pavli et al., 2009), anionic polymers like carrageenans (very similar in
structure to sodium alginates) can form solid solutions with cationic drugs by solvent
casting in excess of water. To further investigate the ability of Keltone to form ionic
complexes with oppositely charged molecules, Eudragit EPO, a cationic polymer was used
as a plasticizer for Keltone.
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Figure 4.1 Ramp heating of DMN, Keltone, Keltone/DMN PM and Keltone/DMN
solvent-casted film.
Figure 4.1 shows the DSC ramp heating of Keltone/DMN 50:50 PM and solvent
casted film as well as of the raw materials of this formulation. The endothermic enthalpy of
DMN in the PM is very close to the melting enthalpy of the pure drug suggesting the
absence of any interaction between the two components (black tracer). However, when the
solvent-casted film was heated there is a very small endotherm (~2 J/g) ~10°C lower than
the melting point of pure DMN that may be related to the dissolution of DMN in
KELTONE (blue tracer). The above strongly suggest that ~50% of DMN was dissolved in
Keltone and remained in solution following the removal of water from the formulation.
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4.2 Characterization of Raw Materials
The thermal properties and morphologies of the raw materials were characterized in this
Section. The characteristic thermal transition temperature of Keltone, Eudragit EPO, DMN
and CLO are presented in Figures 4.1 and 4.2. DSC was used to get characteristic thermal
transition temperatures, including the glass transition temperature of Eudragit EPO, the
melting temperature of DMN and CLO.

Figure 4.2 Heat-cool-heat scan of Keltone and Eudragit EPO, ramp heating of CLO.
The melting point of DMN is ~ 171°C whereas Clotrimazolemelts~145°C. The Tg
of EPO form the second heating is ~ 46°C.Keltone lacks any characteristics transition in
the temperature range examined in this work. The large endotherm during the first heating
is due to the evaporation of water (~13% as detected by TGA).
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The TGA ramp and isothermal heating as well as thermal stability based on color
change of Keltone are presented in Figure 4.3 The onset temperature of weight loss in the
TGA ramp heating tests is above 200C. This test was also conducted under N2 to
determine whether the degradation was oxidative in nature. Since no difference between
the two ramp tests was detected, there is no need to process Keltone under N2. The
isothermal TGA was conducted to further examine the thermal stability a function of time.
The isothermal TGA at the HME barrel temperature (150C) was conducted to further
examine the thermal stability of CLO, as shown in Figure 4.4.The sample was processed
for 10min at 150°C, showing less than1% weight loss at 150°C.

.
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Figure 4.3 (a)Ramp heating of Keltone under air, (b) isothermal heating for 10 min,
(c) degradation-induced color change relative to the original material.
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Figure 4.4 Isothermal heating of CLO for 10 min (vertical/ horizontal axes: weight / time).
4.3 Extrusion
In this section, the possibility of Keltone being extruded with water as a plasticizer and
DMN as an API was examined. We also extruded Keltone with EPO as a plasticizer and
Clotrimazoleas an API. The minimum amount of plasticizer and the processing
temperature of Keltone were optimized. TGA tests were conducted to identify the residual
water content of extrudates. DSC tests were conducted to determine the thermal transitions
of extrudates during heating.

4.3.1 Optimization of Minimum Amount of Plasticizer and Processing Temperature
for Keltone Using Water as Plasticizer

Extrusion optimization runs were performed to identify a) the minimum concentration of
water as a plasticizer for Keltone and b) the optimum extrusion temperature. Table 4.1 lists
the barrel temperatures and compositions used during all extrusion optimzation runs.The
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first three combinations (Formulations #1 to #3) of composition/processing temperature
resulted into extrudates of acceptable consistency and ease of extrusion. Extrusion of
formulation #4 was very unstable and resulted into an extrudate of uneven consistency,
because of a combination of high temperature and low water content. Formulation #5 could
not be extruded as the amount of water was too low (blockage of the extruder). Based on
the preliminary runs without API we decided that the most suitable extruder barrel
temperature profile is the following: 120°, 90° , 80°, 80° , 50°C; the die temperature in
the range of 124-126°C; and the minimum amount of water as plasticizer allowing
extrusion runs is 40%. Formulations #6 and #7 were the two formulations that contained
DMN, based on 40% of water as plasticizer. Formulation #6 was not possible to extrude.
Formulation #7 was also very difficult to extrude and had very low viscosity (oil-like).
Figure 4.5 shows the appearance of extrudates after extrusion.
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Figure 4.5 Appearance of extrudates after extrusion: (a) formulation #1, (b) formulation
#2, (c) formulation #3, (d) formulation #4 and (e) formulation #7 (after drying).
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Table 4.1 Formulations and Extrusion Conditionsof Keltone, DMN And Water
Formulation
(#)

Composition
(Keltone/DMN/water)
(%(w/w))

Composition
(Keltone/DMN/total water) (%(w/w))

1
2
3
4
5

42.9/-/57.1
42.9/-/57.1
60/-/40
60/-/40
66.7/-/33.3

(adjusted for Keltone water content
(~15%))
36.1/-/63.9
36.1/-/63.9
50.5/-/49.5
50.5/-/49.5
56.7/-/43.3

6
7

42/30/28
52.5/37.5/10

35.7/30/34.3
44.6/37.5/17.9

Extrusion conditions
(C°)
M Z4(D) Z3 Z2 Z1 Z0(F)

126°
124°
125°
126°
129°

120°
130°
120°
130°
120°

90° 80° 80° 50°
100° 80° 80° 50°
90° 80° 80° 50°
100° 80° 80° 50°
90° 80° 80° 50°

126° 120° 90° 80° 80° 50°
133° 120° 90° 80° 80° 50°
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Figure 4.6 Torque, pressure, and melt temperature traces for extrudate #1.
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Figure 4.7 Torque, pressure, and melt temperature traces for extrudate #2.
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Figure 4.8 Torque, pressure, and melt temperature traces for extrudate #3.
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Figure 4.9 Torque, pressure, and melt temperature traces for extrudate #4.
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Figure 4.10 Torque, pressure, and melt temperature traces for formulation #5.
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Figure 4.11 Torque, pressure, and melt temperature traces for formulation #6.
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Figure 4.12 Torque, pressure, and melt temperature traces for formulation #7.

Figures4.6-4.12 show the torque, die pressure and melt temperature during
extrusion of formulations #1-#6. In all graphs the torque and die pressure are unstable.
This is probably a result of the fact that the incorporation of water into Keltone is taking
much of the extruder length to complete. Therefore, most of the extruder barrel is filled
with what may be mostly a “wet powder” mixture, while true dissolution of Keltone into
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water takes place only at the end of the barrel. Including additional kneading elements in
the extruder screw to enhance early and adequate mixing of the feed, primarily water
incorporation, maybe a way to circumvent torque and die pressure instabilities.

4.3.2 Thermo-Gravimetric Analysis of Extruded Formulations
Water or moisture is undesirable in finished pharmaceutical products since its presence
can result in product instabilities (e.g., recrystallization of drug, change of mechanical
properties of tablets). For this reason, after extrusion, TGA was used to determine the
residual water content of extrudates #1, #2, #3, #4 and #7. For ramp heating, a heating
rate of 10°C/min was used to heat the samples from 30°C to 250°C. Runs were
occasionally performed in duplicate with good reproducibility.
From the results in Figure 4.13 it can be seen that the more water the formulation
initially contains, the more water the extrudates contain. In addition, for the same
formulation composition, the higher the extrusion temperature, the less water the
extrudates contain. For lower initial water contents (formulation #3 and #4) increasing
the temperature by 10°C at the last two zones of the extruder can result in a ~15%
reduction in residual water (36% vs 21%). It should be noted that when we attempted to
use higher die temperatures (>130°C) to remove all or most of the water at the end of the
barrel, the extruder was blocked. This is due to the fact that Keltone and related
polysaccharides are crystalline polymers that do not possess a practical melting point
(degradation occurs before melting) and as a result they do not flow without a plasticizer
when heated.
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Figure 4.13 TGA ramp heating of pure Keltone, DMN and extruded formulations #1-#4
and #7.
4.3.3 Concluding Remarks
The processability of Keltone extruding with water as a plasticizer was explored. The
most suitable extruder temperature profile along the extruder barrel and die (from the
screw tip to the hopper)for Keltone using water as a plasticizer is the following: 120° ,
90° , 80° , 80°, 50°C, the minimum amount of water as plasticizer allowing extrusion
runs is 40%. The residual water contents in extrudate were determined by TGA test,
which show that the residual water contents in extrudates were from 21% to 48%. Higher
die temperature (>130°C) to remove the water at end of the result in the blockage of the
extrusion.
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4.3.4 Optimization of Amount of Plasticizer and Processing Temperature of
Keltone Using Eudragit EPO as Plasticizer

In this section, extrusion optimization runs were performed to identify a) the optimum
amount of Eudragit EPO as a plasticizer for Keltone and b) the optimum extrusion
temperature. Table 4.2 lists the barrel temperatures and compositions used during all
extrusion optimmzation runs.The first three combinations (Formulations #1 to #3) of
composition/processing temperature could not be extruded as the amount of Eudragit
EPO was too low (blockage of the extruder) and the processing temperature was too low
(materials seem to consolidate). Formulation #4 was succesfully extruded and with ease.
However considerable discoloration was observed potentially as a result of thermal
degradation. By lowering the processing temperature and increasing the amount of
EPO,formulation #5 produced an extrudate with color closer to the original raw
materials. Based onpreliminary runs without API, the most suitable extruder temperature
profile of Keltone with Eudragit EPO as plasticizer was decidedas the following: 150°
150° 130° 80° 50°C. Control formulation #6 containedonly Eudragit EPO and CLO.
Formulation #7 and #8 were the two formulations that contained Keltone, Eudragit EPO
and CLO, using the same ratio of EPO/CLO as in formulation #6. Both of the two runs
were of good consistency and were easily extruded. Figure 4.14 shows the appearance of
extrudates after extrusion.
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Table 4.2Formulationsand Extrusion Conditions of Keltone, CLO and Water
Formulation
(#)

Composition
(Keltone/CLO/EPO)
(%(w/w))

Extrusion conditions
(C°)
M Z4(D) Z3 Z2 Z1 Z0(F)

1
2
3
4
5

90/-/10
85/-/15
70/-/30
50/-/50
40/-/60

145°
165°
161°
166°
159°

6

-/30/70

157° 150° 150°130° 80° 50°

7
8

10/27/63
20/24/56

157° 150° 150° 130° 130° 50
157° 150° 150° 130° 130° 50
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130°
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Figure 4.14 Appearance of extrudates after extrusion: (a) formulation #4, (b)
formulation #5, (c) formulation #6, (d) formulation #7 and (e) formulation #8 (after
drying).
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Figure 4.15 Torque, melt temperature traces for formulation #1.
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Figure 4.16 Torque, melt temperature traces for formulation #2.
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Figure 4.17 Torque, melt temperature traces for formulation #3.
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Figure 4.18 Torque, melt temperature traces for formulation #4.
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Figure 4.19 Torque, melt temperature traces for formulation #5.
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Figure 4.20 Torque, melt temperature traces for formulation #6.
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Figure 4.22 Torque, melt temperature traces for formulation #8.
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Figure 4.21 Torque, melt temperature traces for formulation #7.

Figures 4.15-4.22 show the torque and melt temperature during extrusion of
formulations #1-#8. In Figures 4.15-4.17the torque is unstable. This maybe a result of the
fact of the insufficient amount of Eudragit EPO as a plasticizer. In Figures 4.18-4.22, the
torque of during extrusion of formulation #4-#8 is of acceptable stability, due to the good
consistency of formulation component homogenization during the extrusion.

4.3.5 Observation on Hot Stage Microscopy

Figure 4.23 Transmission optical microscopy evolutions of EPO/CLO/Keltone
(63/27/10), extrudate #7.
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Figure 4.24 Transmission optical microscopy evolutions of EPO/CLO/Keltone
(63/27/20),extrudates #8.

A hot stage was used to observe the morphology evolution in conjunction with the optical
microscope. Figures 4.19- 4.20 show themorphology evolution of extrudate #7and
extrudate #8at the same heating rates, which was set 20C/min from 30 to 160 C,
conducted on a hot stage microscope. No changes in shapes of the crystals were shown in
their morphologies during heating. Since the final temperature is beyond the melting
point of CLO, which is 146C, the crystals seen in these images are crystalline Keltone,
indicating that either a portion or all of the Keltone did not consolidate with EPO during
extrusion.
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4.3.6 Differential Scanning Calorimetry Analysis of Extruded Formulation

Figure 4.25 Ramp heating of EPO/CLO PM and extrudate.

Figure 4.26 Ramp heating of EPO/CLO/KEL PM and extrudates.
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Figure 4.25 shows the ramp heating of EPO/CLO 70/30 PM and extrudates that was used
as a control for the EPO/CLO/KEL formulations. During the heating of the PM there is
an endotherm that corresponds to the dissolution of CLO into EPO. During the heating of
the extrudate, there is no endotherm indicating that 30% CLO is dissolved into EPO. In
addition no traces of crystalline drug were found when looked at the extrudate under the
polarized light microscope (results not shown).
Figure 4.26 shows the ramp heating of the PMs and extrudates of the two
formulations with EPO, CLO and KEL. The dissolution endotherm of the CLO in the
extrudate with 10% Keltone is larger that the one with 20% Keltone since the former
contains more CLO. However, both of the extrudates show no dissolution endotherm for
CLO (there is a very small endotherm in the extrudate with 10% Keltone however, the
value of 0.3 J/g is extremly small to be taken as indication of undissolved CLO). These
results correlate with the absence of any CLO crystals in the PLM images of the
extrudates (Figures 4.23 and 4.24). The uncosolidated Keltone seen in these PLM images
cannot be detected by the DSC as Keltone lacks any characteristic thermal transitions in
the temperature range examined.
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CHAPTER 5
SUMMARY AND FUTURE WORK

The work in this thesis has focused on the assessment of the possibility of using Keltone,
a marine polysaccharide derived from brown seaweed, as a polymeric excipient for
pharmaceutical HME. Water and Eudragit EPO were used as plasticizers, and
Diphenhydramine Hydrochloride and Clotrimazole were used as active pharmaceutical
ingredients (APIs). Extrusion was conducted in the Leistritz Nano16 Co-TSE.TGA was
used to determineresidual water content of the extrudates. DSC was used to characterize
thermal transitions of extrudates during heating. Optical microscopy was used to
determine any undissolved API.
In this work, the minimum amount of plasticizer and processing temperature for
Keltone using water as plasticizer was optimized. The most suitable extruder temperature
profiles is: 120° 90° 80° 80° 50°C, while the minimum amount of water as plasticizer
allowing extrusion runs is 40%.Above a certain processing temperature and below a
certain amount of water, extrusion of Keltone was not possible. Based on above
formulation of Keltone and water, and the suitable processing temperature, extrusions
contained DMN were conducted. However, formulation contained DMN could not be
extruded in consistency. DMN does not dissolve in the extrudates when heated in DSC,
therefore water may play a very important role in this. In the TGA result of the samples
extruded using the mos suitable conditions, the residual water is 21%. As water or
moisture is undesirable in finished pharmaceutical products because of potential product
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instabilities, water may not be a proper candidate as plasticizer for the extrusion of
Keltone.
The processability of Keltone by extrusion using Eudragit EPO was also assessed
in this work. The most suitable extruder temperature profiles was: 150° 150° 130° 80°
50°C, and the optimal amount of Eudragit EPO was found to be 60% wt. Formulations
contained CLO as API were extruded under this condition. The DSC analysis of the
extrudates showed no melting peak for CLO, suggesting that this drug only can fully
dissolve in the excipient matrix in an amorphous state.
An important summary conclusion is the following: as a result of this work we
can state with certainty that Keltone cannot be easily or widely used as polymer
excipient.
Future work can be done as follows:
The plasticizer being used is distilled water with a specific pH of four. As Keltone
is insoluble in acidic pH and soluble in basic pH, the pH of distilled water can be adjusted
to higher one, in which way Keltone may be processed more easily. The combination of
water and Eudragit EPO as a plasticizer also has the potential to allow the extrusion of
Keltone.
Clotrimazole (CLO) is a weak base with two ionizable nitrogen atoms, which
may make CLO exhibit good dissolution behavior under acidic conditions in stomach,
but is likely to precipitate further in gastrointestinal tract because of a sharp increase in
pH under the condition found in the intestine. This may result in poor and erratic
bioavailability. Since the DSC result of extrudates showed that CLO was fully dissolved
in the extrudate, the bioavailability CLO may be improved by this way. Moreover,
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Keltone is a pH-depended solubility (insoluble in low pH, soluble in basic pH) material,
which makes it a good candidate of excipient for target-release of CLO. Further work of
dissolution tests can be conducted to verify the dissolution rate of CLO.
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